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Epithelial Mesenchymal Transition in Chronic
Obstructive Pulmonary Disease, a Precursor for
Epithelial Cancers: Understanding and Translation to
Early Therapy
To the Editor:
We read with interest the recent editorial by Nichole T. Tanner
and colleagues, published in the AnnalsATS, considering the
lethal association between chronic obstructive pulmonary disease
(COPD) and lung cancer that highlighted the potential causal
role of epithelial mesenchymal transition (EMT) in this link (1).
Understanding these mechanisms is much needed for translation
to early, and potentially even preventative, therapy. It is
encouraging and reassuring that leading clinical respiratory
journals are now recognizing this, as it has been difficult to
obtain data on such a novel concept published in high-profile
journals.
Human epidemiological studies strongly suggest that patients
receiving high-dose inhaled corticosteroids have an appreciable
(50%) reduction in the risk for lung cancer (2). We have
hypothesized that EMT might be the process through which this
effect of inhaled corticosteroids occurs. Thus, in a proof-of-
concept randomized controlled trial, we reported that inhaled
fluticasone propionate delivered in high doses over the course of
6 months did suppress airway epithelial activation and EMT-related
changes in large airways of patients with COPD (3). This was
the first study to report anti-EMT effects of inhaled corticosteroids
in COPD. If this hypothesis is indeed correct, it has major
implications for treating/preventing both obstructive airway
fibrosis and lung cancer, although a more safe drug than steroids
in these doses would be ideal for long-term use.
We were the first to report that EMT is an active process in
both small and large airways of smokers and patients with COPD
and was related to reduced lung function in COPD (4, 5). Several
other groups have since confirmed these findings. In the large
airways, we found that active EMT is present and is associated
with hypervascularity of the reticular basement membrane. This
gives the typical appearance of active type 3 EMT, which is
considered a premalignant condition. It is important to note that it
is large airways where most of the squamous cell carcinomas
occur, and type 3 EMT could be central to this. The other
key pathology associated with COPD is small airway or
peribronchiolar fibrosis and obliteration, and this could potentially
be related to active type 2 EMT at this site, but fibrosis in general is
also associated with malignancy (5).
Very recently, we also reported active EMT in the leading edge
of invasive nonsmall cell lung cancer, both squamous and adeno
cell types, with the aggressiveness of the tumors being strongly
related to the activity of their EMT (6). Further, EMT activity
within the tumors closely related to EMT activity in nontumor-
affected airway wall epithelium. This work suggests that the level
of EMT activity in the airway wall, even in large airways
amenable to bronchoscopic biopsy, could potentially be used as a
marker for smokers most likely to develop both COPD and lung
cancer.
In summary, we appreciate that major journals are beginning
to recognize that epithelial activation and basal cell
reprogramming with EMT (and epithelially related vessel
changes) may represent fundamentally important aspects of
COPD pathology, including the severe sequelae of airway fibrosis
and cancer development. Indeed, we may now be getting into a
position that allows an integrated understanding of this airway
disease, with the potential to be translated into a new paradigm for
earlier or even preventive therapy, attacking fundamental disease
mechanisms rather than symptoms and clinical exacerbations in
later-stage patients.
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Unilateral High-Altitude Pulmonary Edema
To the Editor:
We readwith great interest the paper byCherian and Estrada-Y-Martin
(1) discussing a case of unilateral pulmonary edema at high altitude.
We have also reported a case of unilateral high-altitude
pulmonary edema (HAPE) in a subject with a previously known
right pulmonary artery hypoplasia (2). The discussion of our case
confirms the theory of overperfusion cited in the Cherian article;
in fact, pulmonary edema was limited to the lung without
pulmonary artery hypoplasia. Both cases underline the importance
of hemodynamic factors in the development of HAPE. There is a
strong individual predisposition to HAPE, with a marked
pulmonary vascular response to hypoxia and exercise (3).
Susceptibility to HAPE is also reported in people with congenital
or acquired limitation of the pulmonary vascular bed and/or
pulmonary hypertension (3, 4). In these conditions, development
of HAPE is possible at an altitude lower than the one related
in classical cases (3, 4). Another condition reported as a possible
risk factor for HAPE is the presence of a patent foramen ovale (5).
Patent foramen ovale is not uncommon, as it is present in
approximately 25% of the general population. Some papers suggest
that in the presence of patent foramen ovale, sudden ascent to
high altitude may create a vicious circle, with the pulmonary
hypertension, induced by the hypobaric alveolar hypoxia, leading
to a right-to-left shunt that worsens the hypoxemia. In fact, the
major determinant of hypoxic vasoconstriction is alveolar
hypoxia (6), but systemic and bronchial arterial PO2 and mixed
venous PO2 (reduced by exercise in a hypobaric environment) also
contribute to a lesser degree and in an additive fashion (6).
Even in the absence of studies specifically assessing the risk,
patients with known congenital or acquired conditions that may
cause overperfusion and/or hypertension of the pulmonary
vascular bed should be advised to take preventive measures before
high-altitude travels (3, 4).
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Reply: Unilateral Pulmonary Edema after Visiting
High Altitude
From the Authors:
We thank Drs. Fiorenzano and Dottorini for their interest and
comments about our article, “Unilateral Pulmonary Edema
after Visiting High Altitude” (1) in the Clinical Physiologist
section.
We agree that their published report (2), which described
the development of unilateral high-altitude pulmonary edema
(HAPE) in the setting of right pulmonary artery hypoplasia, is
very similar to our case. Their case also reports the development
of pulmonary edema in the lung with the normal pulmonary
circulation. We agree with them that hypoxia-associated
pulmonary vasoconstriction is key to the development of HAPE
in susceptible individuals. This is heightened in congenital
conditions associated with increased pulmonary blood flow, as
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